How the Neuropeptide Substance P Activates Cancer-Driving Receptors in Breast Cancer Cells

The neuropeptide Substance P activates the cancer-driving receptors HER2 and EGFR in breast cancer cells through two pathways requiring c-Src kinase and metalloproteinases (MMPs). Inhibiting c-Src alone prevented Substance P-induced HER2 activation, while MMP inhibition reduced phosphorylation of both HER2 and EGFR. Dual inhibition of both c-Src and MMPs nearly abolished HER2 and EGFR activation and also reduced breast cancer cell viability and migration. These findings reveal that Substance P's tumor-promoting effects in breast cancer depend on both ligand-independent (c-Src) and ligand-dependent (MMP) signaling pathways.

In vitro cell biology study using four breast cancer cell lines (MDA-MB-231, SK-BR-3, BT-474, MDA-MB-468). NK-1 receptor was overexpressed in one line and chemically inhibited in others. The roles of c-Src and metalloproteinases in Substance P-mediated HER2/EGFR activation were tested using specific inhibitors (c-Src inhibitor and MMP inhibitor 1,10-phenanthroline monohydrate). Cell viability and migration were assessed under single and dual inhibition conditions.

HER2 and EGFR are major targets in breast cancer treatment, but drug resistance remains a significant clinical challenge. This study reveals that the neuropeptide Substance P can activate these receptors through an alternative route — the NK-1 receptor — bypassing the pathways that current targeted therapies block. Understanding this cross-talk mechanism could inform new combination treatment strategies to overcome drug resistance in HER2+ and EGFR+ breast cancers.

The tumor microenvironment contains many signaling molecules, including neuropeptides like Substance P, that can influence cancer behavior in ways not targeted by standard therapies. This research highlights how a neuropeptide can bypass the pathways that current drugs block, potentially contributing to treatment resistance. The growing recognition of neuropeptide signaling in cancer biology is opening new avenues for combination therapies that target these alternative activation routes.

This is an in vitro study using cultured breast cancer cell lines, which may not fully represent the complexity of tumors in patients. The interactions between Substance P, the tumor microenvironment, and the immune system were not captured. No animal models or patient samples were used to validate the findings in a more physiological context.